AIM ImmunoTech Inc. (AIM)
NYSEAMERICAN: AIM · Real-Time Price · USD
0.1563
-0.0047 (-2.92%)
Oct 23, 2026, 4:00 PM EDT - Market closed
AIM ImmunoTech Revenue
AIM ImmunoTech had revenue of $26.00K in the quarter ending June 30, 2026, with 4.00% growth. This brings the company's total for the last twelve months to $95.00K, down -21.49% year-over-year. In the year 2025, AIM ImmunoTech had annual revenue of $88.00K, down -48.24%. That makes AIM ImmunoTech the 46,068th largest company in the world by revenue and 6,810th in the United States.
Revenue (ttm)
$95.00K
Revenue Growth
-21.49%
P/S Ratio
50.09
Revenue / Employee
$4,524
Employees
21
Market Cap
4.76M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 88.00K | -82.00K | -48.24% |
| Dec 31, 2024 | 170.00K | -32.00K | -15.84% |
| Dec 31, 2023 | 202.00K | 61.00K | 43.26% |
| Dec 31, 2022 | 141.00K | 6.00K | 4.44% |
| Dec 31, 2021 | 135.00K | -28.00K | -17.18% |
| Dec 31, 2020 | 163.00K | 23.00K | 16.43% |
| Dec 31, 2019 | 140.00K | -227.00K | -61.85% |
| Dec 31, 2018 | 367.00K | -70.00K | -16.02% |
| Dec 31, 2017 | 437.00K | 345.00K | 375.00% |
| Dec 31, 2016 | 92.00K | -41.00K | -30.83% |
| Dec 31, 2015 | 133.00K | -64.00K | -32.49% |
| Dec 31, 2014 | 197.00K | 47.00K | 31.33% |
| Dec 31, 2013 | 150.00K | -63.00K | -29.58% |
| Dec 31, 2012 | 213.00K | 52.00K | 32.30% |
| Dec 31, 2011 | 161.00K | 26.00K | 19.26% |
| Dec 31, 2010 | 135.00K | 24.00K | 21.62% |
| Dec 31, 2009 | 111.00K | -154.00K | -58.11% |
| Dec 31, 2008 | 265.00K | -794.00K | -74.98% |
| Dec 31, 2007 | 1.06M | 126.00K | 13.50% |
| Dec 31, 2006 | 933.00K | -150.00K | -13.85% |
| Dec 31, 2005 | 1.08M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Xenetic Biosciences | 3.26M |
| Traws Pharma | 2.73M |
| Evogene | 1.66M |
| Longeveron | 1.19M |
| Lexaria Bioscience | 194.00K |
| Cardio Diagnostics Holdings | 14.45K |
| Creative Medical Technology Holdings | 3.00K |
| Pulmatrix | 3.00K |
AIM News
- 17 days ago - AIM ImmunoTech's Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays - GlobeNewsWire
- 19 days ago - AIM ImmunoTech Highlights Recent Media Coverage of Ampligen's® Broad-Spectrum Antiviral and Biodefense Potential - GlobeNewsWire
- 23 days ago - AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data - GlobeNewsWire
- 24 days ago - AIM ImmunoTech Discusses Ampligen®'s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video - GlobeNewsWire
- 24 days ago - AIM ImmunoTech Proxy statement: Proxy filing - Filings
- 4 weeks ago - AIM ImmunoTech CEO issues letter to stockholders - TheFly
- 4 weeks ago - AIM ImmunoTech Highlights Ampligen's Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines' Daraxonrasib - GlobeNewsWire
- 6 weeks ago - AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video - GlobeNewsWire